Disclosed herein are methods for selecting an antibody fragment specific to an influenza virus. According to certain embodiments of the present disclosure, the influenza virus may be influenza virus type A (IAV) or influenza virus type B (IBV). Also disclosed herein are the selected antibodies, recombinant antibody produced from the selected antibodies, and the uses thereof in the diagnosis of influenza virus infection.

Provided are methods of making a SARS-CoV-2 (COVID-19) infection classifier for a platform, and optionally a non-COVID-19 viral infection classifier, a bacterial infection classifier, a non-infectious illness classifier, and/or a healthy subjects classifier for the platform. Methods and systems for determining the presence of SARS-CoV-2 (COVID-19) infection in a subject or for determining the viral stage of infection of a SARS-CoV-2 (COVID-19) illness in a subject suffering therefrom are also provided.

Methods, systems and devices for determining COVID disease, including receiving symptom data values, calculating first differentials (positive or negative) for the first virus strain by comparing the values to first predetermined symptom threshold values for the first virus strain, using the first differentials to detect a second virus strain with a mutated virus genome code based on a correspondence of its symptoms to the first differentials, calculating second differentials (positive or negative) for the second virus strain by comparing the values to second predetermined symptom threshold values for the second virus strain, creating a superset of the first and second differentials, detecting correlations within the superset, determining that the person has the first or second virus strain when at least one detected correlation indicates that the person has contracted the first or second virus strain, outputting a result indicating a presence or absence of COVID in a person.

Novel Coronavirus/MERS-CoV/Influenza Virus A/B Multiple Rapid Detection Kit is disclosed. The kit has the advantages of high sensitivity, good specificity, high speed (3-15 minutes), simplicity and low cost.

A method for treating an early-stage microbial infection comprising determining whether a subject exposed to SARS-CoV-2, Monkeypox virus (MPV, MPXV, or hMPXV) or suspected of being exposed to a microbe, or exposed to another infected with or suspected of being infected with a coronavirus and/or Monkeypox virus, if the subject is infected with the coronavirus and/or Monkeypox virus, administering an antimicrobial agent is provided herein.

Disclosed are real-time insect surveillance sensor devices and methods that use a colorimetric readout for detecting insect disease vectors (such as mosquitoes which can transmit pathogens such as DENV, CHIKV, and ZIKV). The method involves an attractive or feeding solution combined with detector conjugates. The conjugate can specifically detect proteins present in insect saliva and/or proteins specific to mosquito-borne pathogens.

A method for image analysis of medical test results, comprising receiving information from a mobile device application regarding a test performed using a testing device, wherein the testing device includes a plurality of immunoassay test strips and at least one test function indicator on a surface thereof, wherein the mobile device application is configured to recognize the at least one test function indicator to trigger performance of one or more of the plurality of medical test functions, receiving at the server an image of the testing device from the mobile device application, determining by the server RGB values for a plurality of pixels of the image, normalizing by the server the RGB values into a single value, comparing the single value to a control value, and providing by the server a risk indicator, wherein the risk indicator indicates a likelihood of a presence of a medical condition.

The present disclosure is directed to antibodies binding to and neutralizing Zika virus and methods for use thereof.

Provided herein are methods and compositions for inhibiting p97, for the treatment of a coronavirus infection in a subject, or a symptom thereof. Upon treatment, the coronavirus infection, or a symptom thereof is reduced in the subject.

Described herein are nucleic acids encoding single-domain antibodies that might serve as alternatives to conventional monoclonal antibodies for either the detection or treatment of Chikungunya Virus (CHIKV).